← All indications
Primary Myelofibrosis
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Drugs by status
Approved for this indication (4)
Phase 3 trials (24)
- fostemsavir
- danazol
- deferasirox
- tacrolimus
- hydroxyurea
- Imetelstat
- img-7289
- Filgrastim
- luspatercept
- navitoclax
- allogeneic hematopoietic stem cells
- acetylsalicylic acid
- mycophenolate
- cyclophosphamide
- alemtuzumab
- Anti-thymocyte Globulin (Rabbit)
- fludarabine
- sargramostim
- pomalidomide
- navtemadlin
- interferon alpha-2b
- parsaclisib
- jaktinib
- autologous hematopoietic stem cells
Phase 2 trials (117)
- allopurinol
- thalidomide
- decitabine
- azacitidine
- methylprednisolone
- lysergic acid diethylamide
- cmv-specific t-cells
- ridaforolimus
- acetylcysteine
- Gusacitinib
- at9283
- venetoclax
- mirabegron
- busulfan
- bvd-523
- canakinumab
- captopril
- lenalidomide
- clofarabine
- prednisone
- selinexor
- eltrombopag
- parathyroid hormone
- vismodegib
- imatinib
- naltrexone
- hemopoietic stem cell
- beclomethasone
- incb057643
- nivolumab
- +87 more
Phase 1 trials (81)
- abemaciclib
- afatinib
- olaparib
- azd-1480
- sorafenib
- belinostat
- talazoparib
- bms-986158
- cd25-depleted peripheral blood mononuclear cell
- cwp232291
- durvalumab
- elotuzumab
- enmd 2076
- enzalutamide
- gc1008
- fluorouracil
- trametinib
- rifampin
- myeloid progenitor cells
- idelalisib
- interferon alpha-2a
- hyaluronidase (human recombinant)
- ribociclib
- lenvatinib
- leucovorin
- pim447
- montanide isa51
- nis793
- vitamin c
- palbociclib
- +51 more
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (16)
- AbbVie
- Celgene
- Gilead Sciences
- Sanofi
- CTI BioPharma
- Constellation Pharmaceuticals
- Geron Corporation
- Sierra Oncology, Inc.
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- National Cancer Institute (NCI)
- The Canadian Blood and Marrow Transplant Group
- University of Southern Denmark
- University of Toronto
- Zhejiang University
- University of Texas at Houston
- Government of Canada
Organization Involved with Phase 2 Indications (84)
- S*BIO
- Galecto Biotech
- YM Biosciences
- Cephalon
- Bristol-Myers Squibb
- Roche
- Merck
- Pfizer
- Ariad Pharmaceuticals
- Asana BioSciences
- Ascentage Pharma Group Inc.
- Baxalta
- Infinity Pharmaceuticals, Inc.
- Karyopharm Therapeutics Inc
- Onconova Therapeutics, Inc.
- Promedior, Inc.
- Rigel Pharmaceuticals
- PharmaMar
- Stemline Therapeutics, Inc.
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Arizona
- Case Western Reserve University
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- French Innovative Leukemia Organisation
- Gruppo Italiano Trapianto di Midollo Osseo
- Katholieke Universiteit Leuven
- +54 more
Organization Involved with Phase 1 Indications (31)
- Boston Biomedical
- Daiichi Sankyo
- Takeda
- Millennium Pharmaceuticals
- AstraZeneca
- Eli Lilly
- Exelixis
- Genzyme
- CASI Pharmaceuticals, Inc.
- JW Pharmaceutical
- Sponsor GmbH
- TargeGen
- Apex Bioscience
- Forbius
- Imago BioSciences
- University of Pittsburgh
- AIDS Malignancy Consortium
- Northwestern University
- University of Maryland
- Wake Forest University
- University of Copenhagen
- Vanderbilt University
- SGS Life Sciences
- Institut Gustave Roussy
- The Leukemia and Lymphoma Society
- Samus Therapeutics
- Carol Davila University of Medicine and Pharmacy
- Center for Cancer Immune Therapy, Denmark
- The University of Texas, Dallas
- Myeloproliferative Neoplasm Research Consortium (MPN-RC)
- +1 more
Organization Involved with Other Experimental Indications (2)